Home/Filings/4/0001213900-22-019913
4//SEC Filing

Bench David 4

Accession 0001213900-22-019913

CIK 0000316253other

Filed

Apr 13, 8:00 PM ET

Accepted

Apr 14, 7:58 PM ET

Size

12.8 KB

Accession

0001213900-22-019913

Insider Transaction Report

Form 4
Period: 2022-04-13
Bench David
CHIEF FINANCIAL OFFICER
Transactions
  • Award

    Common Stock, $0.01 Par Value

    2022-04-13$2.90/sh+880$2,552880 total(indirect: By Trust)
  • Award

    Common Stock, $0.01 Par Value

    2022-04-14$2.90/sh+1,620$4,6982,500 total(indirect: By Trust)
Holdings
  • Stock Option (to acquire Common Stock)

    Exercise: $3.36From: 2023-02-11Exp: 2027-02-11Common Stock (87,500 underlying)
    87,500
  • Stock Option (to acquire Common Stock)

    Exercise: $2.20From: 2021-02-24Exp: 2025-02-24Common Stock (55,400 underlying)
    55,400
  • Stock Option (to acquire Common Stock)

    Exercise: $2.98From: 2023-03-24Exp: 2027-03-24Common Stock (87,500 underlying)
    87,500
  • Stock Option (to acquire Common Stock)

    Exercise: $2.63From: 2022-01-11Exp: 2026-01-11Common Stock (55,400 underlying)
    55,400
  • Common Stock, $0.01 Par Value

    (indirect: By 401(k))
    4,138
Footnotes (3)
  • [F1]Represents shares held by David Bench Consulty Group, a profit sharing plan of which the reporting person is a participant.
  • [F2]Represents restricted shares granted subject the Company's discretionary matching contribution and non-elective employer contribution which vest ratable over four years of service, which began on December 23, 2019.
  • [F3]The stock options have a five-year term and will vest in three equal instalments, one on the first anniversary of the grant date, the second on the second anniversary of the grant date and the third on the third anniversary of the grant date.

Documents

1 file

Issuer

ENZO BIOCHEM INC

CIK 0000316253

Entity typeother

Related Parties

1
  • filerCIK 0001797876

Filing Metadata

Form type
4
Filed
Apr 13, 8:00 PM ET
Accepted
Apr 14, 7:58 PM ET
Size
12.8 KB